This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

BL-1020, a New γ-Aminobutyric Acid-Enhanced Antipsychotic: Results of 6-Week, Randomized, Double-Blind, Controlled, Efficacy and Safety Study

Yona Geffen, PhD; Richard Keefe, PhD; Jonathan Rabinowitz, PhD; Ravi Anand, MD; and Michael Davidson, MD

Published: September 15, 2012

Article Abstract

Objective: BL-1020 is a γ-aminobutyric acid (GABA)-enhanced antipsychotic that combines dopamine antagonism with GABA agonist activity. On the basis of animal models, we tested the hypotheses that BL-1020 would be effective in ameliorating both psychotic symptoms and cognitive impairments, with a favorable safety profile in acutely ill schizophrenia patients.

Method: 363 hospital-based psychiatric patients in India, Romania, and United States aged 18 to 65 years and meeting criteria for DSM-IV-TR diagnosis of chronic schizophrenia were randomized double-blind to receive BL-1020 10 mg/d, BL-1020 20-30 mg/d, placebo, or risperidone (2-8 mg/d) for 6 weeks. The main outcome measures were the Positive and Negative Syndrome Scale (PANSS), Brief Assessment of Cognition in Schizophrenia, Readiness for Discharge Questionnaire, Clinical Global Impressions Scale (CGI) , and Extrapyramidal Symptom Rating Scale. The study ran from July 2008 to June 2009.

Results: BL-1020 20-30 mg was significantly better than placebo on PANSS (P=.02) and CGI (P<.001) measurements, with no significant differences noted between BL-1020 20-30 mg and risperidone. There were no significant differences in the maximum change on Extrapyramidal Symptom Rating Scale between risperidone and BL-1020 20-30 mg, and both were significantly worse (P<.001) than placebo. BL-1020 20-30 mg was associated with significantly greater improvements on cognitive functioning as measured by the Brief Assessment of Cognition in Schizophrenia composite score when compared to placebo (effect size=0.50, P=.009), risperidone (effect size=0.43, P=.019), and BL-1020 10 mg (effect size=0.42, P=.013) after 6 weeks.

Conclusions: BL-1020 appears to be an effective antipsychotic with possible procognitive effects that will need to be further tested for short- and long-term effects. A further randomized controlled trial using the US Food and Drug Administration-recommended Measurement and Treatment Research to Improve Cognition in Schizophrenia cognitive battery is ongoing.

Trial Registration: identifier: NCT00567710

J Clin Psychiatry 2012;73(9):e1168-e1174

Submitted: January 9, 2012; accepted: May 1, 2012 (doi:10.4088/JCP.12m07642).

Corresponding author: Yona Geffen, PhD, Avraham Pharmaceuticals, 42 Hayarkon St, Industrial Zone, Yavneh, 81227, Israel (

Volume: 73

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF